Nevertheless, an earlier study reported that alternative splicing might result in reduced dCK activity in patients with resistant AML [43], and cell lines derived from a patient before and after high-dose ara-C therapy showed reduced dCK expression in two resistant cell clones post therapy [300]. The gene discussed is DCK; the disease is acute myeloid leukemia.